VIGL(Delisted)
Vigil Neuroscience·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 0
Bearish signal 1
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VIGL
Vigil Neuroscience, Inc.
A microglia-focused therapeutics company focused on developing treatments for neurodegenerative diseases
100 Forge Road, Suite 700, Watertown, MA 02472
--
Vigil Neuroscience, Inc., was incorporated under the laws of the State of Delaware on June 22, 2020. The company is a clinical-stage biotechnology company dedicated to improving the lives of patients, caregivers and families with rare and common neurodegenerative diseases by developing disease-improving therapies to restore microglia vigilance. The company's first therapeutic drug candidates are designed to activate trigger receptor (TREM 2) expressed on marrow-like cells 2, a key microglia receptor protein that mediates responses to environmental signals to maintain brain health, and its dysfunction is associated with neurodegeneration. The company has two major projects aimed at TREM 2. The Company's lead product candidate, VGL101, is a fully human monoclonal antibody (mAb) TREM 2 agonist (or activator), currently under study in a Phase 2 proof-of-concept trial for a rare and fatal neurodegenerative disease — adult leukoencephalopathy patients with axonal spheres and pigment glial cells (ALSP). The company's second project focuses on small molecule TREM 2 agonists and is currently in investigational new drug (IND) licensing studies.
Company Financials
EPS
VIGL has released its 2025 Q2 earnings. EPS was reported at -0.56, versus the expected -0.47, missing expectations. The chart below visualizes how VIGL has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
